Project Grant R01CA299956
Award Date
6/1/25
Completion Date
4/30/30
Dollars Obligated
$858K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This is a federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), in the amount of $661,845. The award period is from January 15, 2025 to December 31, 2029. The primary objective of this grant is to examine the role of access to care, patient/family interactions with the healthcare system, and stress in explaining variations in the quality of end-of-life (EOL) care for children with cancer. The University of...
This federal Project Grant award of $621,732 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund a hybrid effectiveness-implementation trial to evaluate a proactive identification and digital mental health intervention approach to address unmet psychosocial needs of individuals living with likely incurable cancer. The key products and services to be delivered under this 5-year grant include: 1) comprehensively assessing the...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, aims to refine and pilot test a palliative care intervention called PEACE to address the unmet needs of patients receiving adoptive cellular therapy (ACT) for hematologic malignancies and their caregivers. The $293,053 grant, awarded on August 16, 2024, will support a 5-year plan to: 1) refine the PEACE intervention based on findings from an open pilot...
This $238,824 National Cancer Institute (NCI) Cancer Research Manpower (CFDA 93.398) Project Grant, awarded to The General Hospital Corporation (doing business as Massachusetts General Hospital) on December 1, 2024, will fund a two-year research fellowship to investigate the impact of lung cancer staging procedures on treatment decisions and quality-adjusted life years. The project aims to compare the ability of two lymph node biopsy procedures, endobronchial ultrasound guided transbronchial...
The National Cancer Institute (NCI) awarded a $251,519 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop, refine, and pilot-test a nurse-led coping and supportive care intervention called TRANSITIONS. This intervention aims to address the psychosocial needs of patients with triple-negative breast cancer as they transition from curative therapy to surveillance. The 5-year...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $578,467.00 to Duke University to conduct a randomized controlled trial of the ENGAGE psychosocial intervention for patients with advanced cancer. The ENGAGE intervention, delivered via telehealth, aims to help patients manage co-occurring symptoms like pain, fatigue, and distress that can interfere with their daily lives and quality of life. The trial will evaluate the efficacy of...
The National Cancer Institute (NCI) awarded The Ohio State University a $656,014 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to conduct a randomized clinical trial of a telemedicine-mobile health (mHealth) intervention for symptom management in advanced cancer patients, with a focus on improving outcomes in underserved rural communities. The 5-year project, titled "Randomized Clinical Trial of a Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer...
The National Cancer Institute (NCI) awarded a $1,338,648 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Pittsburgh to conduct a hybrid type I cluster randomized effectiveness-implementation trial of the CARES intervention. CARES is an integrated electronic health record-based screening and stepped collaborative care intervention aimed at improving health-related quality of life for cancer patients experiencing depression, pain, and/or...
The National Cancer Institute (NCI) awarded a $678,927 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Medical College of Wisconsin, Inc. to conduct a 5-year study titled "Symptom Monitoring Using Patient-Reported Outcomes to Optimize Medication Use (SYMPTOM)." The project aims to improve adherence to oral endocrine therapy among breast cancer patients by routinely collecting patient-reported symptom data and providing clinical pharmacy-led support to manage symptoms and...
The U.S. National Cancer Institute (NCI) awarded a $641,508 Cooperative Agreement to The General Hospital Corporation (Massachusetts General Hospital) under the federal Cancer Cause and Prevention Research program (CFDA 93.393). The award, with a project period from September 2024 to August 2029, will support research to understand the long-term risk-benefit balance of aspirin use on cancer and overall health outcomes over a 15-year horizon. As a renowned academic medical center and major...